Century Therapeutics, Inc. (IPSC) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
IPSC EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
IPSC Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -15.8% | -8.8% |
| 2024 | 100.0% | -2096.5% | -1920.9% |
| 2023 | 100.0% | -6556.9% | -6115.1% |
| 2022 | 100.0% | -2574.2% | -2518.4% |
| 2021 | - | - | - |
Download Data
Export IPSC earnings history in CSV or JSON format
Free sign-in required to download data
Century Therapeutics, Inc. (IPSC) Earnings Overview
As of May 8, 2026, Century Therapeutics, Inc. (IPSC) reported trailing twelve-month net income of -$10M, reflecting +91.3% year-over-year growth. The company earned $-0.11 per diluted share over the past four quarters, with a net profit margin of -8.8%.
Looking at the long-term picture, IPSC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$10M in fiscal 2025, representing a new all-time high.
Century Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$136M net income, -2051.1% margin), NKTR (-$164M net income, -297.1% margin), CELC (-$163M net income), IPSC has outperformed on profitability metrics. Compare IPSC vs FATE →
IPSC Earnings vs Peers
Earnings metrics vs comparable public companies
IPSC Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$10M | +92.4% | -$17M | $-0.14 | -8.8% | -15.8% |
| 2024 | -$127M | +7.4% | -$138M | $-1.61 | -1920.9% | -2096.5% |
| 2023 | -$137M | -4.4% | -$147M | $-2.30 | -6115.1% | -6556.9% |
| 2022 | -$131M | -36.6% | -$134M | $-2.27 | -2518.4% | -2574.2% |
| 2021 | -$96M | -78.9% | -$95M | $-1.74 | - | - |
| 2020 | -$54M | +78.1% | -$49M | $-1.00 | - | - |
| 2019 | -$245M | - | -$20M | $-4.49 | - | - |
See IPSC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IPSC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IPSC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIPSC — Frequently Asked Questions
Quick answers to the most common questions about buying IPSC stock.
Is IPSC growing earnings?
IPSC EPS is $-0.11, with earnings growth accelerating to +91.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-10M.
What are IPSC's profit margins?
Century Therapeutics, Inc. net margin is -8.8%, with operating margin at -15.8%. Below-average margins reflect competitive or cost pressures.
How consistent are IPSC's earnings?
IPSC earnings data spans 2019-2025. The accelerating earnings trend is +91.3% YoY. Historical data enables comparison across business cycles.